Nuvation Bio and Daiichi Sankyo side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Nuvation Bio | Daiichi Sankyo |
|---|---|---|
| Phase 1 | 00% | Daiichi Sankyo: 7 of its 20 programs at phase 1
and 2 more — sign in to see them all |
| Phase 2 | 00% | Daiichi Sankyo: 5 of its 20 programs at phase 2 |
| Phase 3 | Nuvation Bio: 2 of its 2 programs at phase 3
| Daiichi Sankyo: 5 of its 20 programs at phase 3
|
| Approved, new studies | 00% | Daiichi Sankyo: 3 of its 20 programs at approved, new studies
|
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nuvation Bio1 readouts · 0 phase 3 | · | · | · | Nuvation Bio, Feb ’27: 1 program whose next study reaches primary completion
| · | · | · | · | · | · | · | · |
| Daiichi Sankyo3 readouts · 1 phase 3 | · | Daiichi Sankyo, Dec ’26: 1 program whose next study reaches primary completion
| · | · | · | · | Daiichi Sankyo, May ’27: 1 program whose next study reaches primary completion
| · | · | · | · | Daiichi Sankyo, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3
|
Changed in the last 90 days
Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Nuvation Bio
New programs 0
None
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 0
None
Daiichi Sankyo
New programs 1
- olomorasibphase 2 · first study · Oct 16 · Carcinoma, Non-Small-Cell Lung
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 3
- patritumab deruxtecanphase 2 · Sep 2027 → Nov 2030 (+39 mo) · moved Nov 17 · NCT06172478
- trastuzumab deruxtecanphase 3 · Aug 2026 → Feb 2028 (+18 mo) · moved Oct 26 · NCT06174987
- Anti-TA-MUC1/DXd Antibody-drug Conjugate DS-3939aphase 2 · Oct 2026 → Aug 2028 (+22 mo) · moved Oct 15 · NCT05875168
Where they overlap
Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.
| Condition | Nuvation Bio | Daiichi Sankyo |
|---|---|---|
| Carcinoma, Non-Small-Cell Lungboth · compare here | Nuvation Bio in Carcinoma, Non-Small-Cell Lung: 1 program
Their studies: Nuvation Bio’s studies of Carcinoma, Non-Small-Cell Lung in search | Daiichi Sankyo in Carcinoma, Non-Small-Cell Lung: 7 programs
and 2 more — sign in to see them all Their studies: Daiichi Sankyo’s studies of Carcinoma, Non-Small-Cell Lung in search |
| Neoplasmsboth · compare here | Nuvation Bio in Neoplasms: 1 program
Their studies: Nuvation Bio’s studies of Neoplasms in search | Daiichi Sankyo in Neoplasms: 1 program
Their studies: Daiichi Sankyo’s studies of Neoplasms in search |
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
No gene two of them both target, among the programs whose target is known.
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.